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Abstract: The number of people in the US with opioid abuse exceeds 2 million and the total cost is
approximately $100B per year. In this study, we focus on patient-level interventions and present three IT-based
interventions: (a) mobile reminders, (b) electronic monitoring, and (c) composite intervention. We have
developed an analytical model for evaluating interventions using Return-on-Investment (ROI). The
interventions are cost-effective for higher values of intervention effectiveness, hospital, and emergency room
cost. However, with QoL improvement, cost-effectiveness improves significantly. We also explored the use of
financial incentives for increasing the adoption of interventions. These results will help patients, healthcare
professionals, decision-makers, and family members to choose the most suitable intervention to address opioid
abuse.
Keywords: Opioid abuse, interventions, patient level, evaluation, analytical model

INTRODUCTION
Prescription opioid abuse is any intentional use of opioids outside of a physician’s prescription for a bonafide medical
condition (Finley et al., 2017; Sinha, Jensen, Mullin, & Elkin, 2017). It can lead to addiction, higher healthcare costs,
and serious harm to patients (Blendon & Benson, 2018). This abuse requires detoxification and hospitalization similar
to a chronic condition. The number of people in the US with opioid abuse exceeds 2 million and the total cost is
approximately $100B per year (NIH, 2019). According to NIH, about half of the drug overdose deaths in the US are
due to opioids (NIH, 2019). The opioid abuse is a major challenge for patients and family members, healthcare
professionals, employers, regulators, and the society. There is a need for interventions at multiple levels before patients
develop opioid addiction and require major treatment.
Each patient has a certain chance of abusing opioids (single vs multiple prescriptions) based on their history, genetic
makeup, current environment, medical condition and type of opioid prescribed. Some of the patients will have low,
some moderate and some will have high level of opioid abuse. This is also time-dependent and patients can change
from low to moderate to high or high to moderate. This has some chance to lead to addiction, which will require
expensive inpatient treatment. This abuse should be considered a chronic disease and different patients will require
outpatient treatment for different duration of time. A different set of actions will be needed (a) at the source (for
healthcare professionals) managing the prescriptions, (b) patient-level during consumption of opioids and (c) after the
patient has developed an addiction. In this paper, we focus on patient-level interventions, which are proactive and with
some probabilities will be effective for some patients in preventing them from developing an opioid addiction. To
design technological interventions, we present a design approach. Using multiple constraints and considering the
environmental context, we have developed three technological interventions. The interventions are (a) mobile
reminders (Voelker, 2019), (b) electronic monitoring of opioids (Jungquist et al., 2019), and (c) composite intervention
(monitoring, reminders and support from other patients) (Schuman-Olivier et al., 2018; Varshney, 2015). The mobile
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reminders will be sent to the patient to provide educational and motivational support to avoid overconsumption of
opioids. The electronic monitoring will keep track of the prescribed opioids. This involves designing wireless
monitoring systems for collecting and analyzing opioid consumption data. The composite intervention will include
reminder, monitoring and motivational support from other patients. This intervention can reduce the consumption of
prescription opioids by monitoring and reminding patients about taking and/or not taking certain doses within certain
windows of time. The interventions can be implemented using both simple and sophisticated mobile apps, sensors,
mobile devices, and smart medication boxes. This could proactively stop patients from becoming dependent on opioids
or develop an addiction.
Using prescription opioid abuse and intervention data, we derive the healthcare cost of opioid abuse along with the
cost of three interventions. Using an analytical model and ROI (Return on Investment) as a metric for costeffectiveness of interventions, we derive several results for all three interventions and various levels of effectiveness.
We found that ROI is lower than 1 for low and medium values of our parameters, while it is much more favorable
when the values of the parameters are set to high. When the value due to a potential improvement in Quality of Life
was included, the ROI significantly improved for all three interventions. Further, we wanted to explore if the use of
financial incentives will be suitable to improve the adoption of three interventions. For this, we computed the
maximum allowed financial incentives that can be offered to the patients while still meeting the cost-effectiveness
goal for the interventions.

DESIGN APPROACH
The design of technological intervention starts with the identification of the environmental factors, patient’s condition
and history followed by possible solutions. These include communication and notification with patients, observing
consumption behavior, providing individual/group education and support, analyzing patterns of opioid consumption,
and cognitive behavior therapy. These interventions can be single or composite (using two or more interventions).
The interventions can be in the form of a mobile app implementing reminders, CBT, and monitoring functions. The
composite intervention can include group support. All interventions can include analytics to study effectiveness of
interventions. The interventions can be personalized to improve suitability to different patients and reduce the overall
cost. If an intervention is not working as desired, it can be changed to the more desirable intervention. This entire
process is shown in Figure 1.

INTERVENTIONS
In this study, we consider three interventions for managing opioid abuse. These interventions are based on (a) mobile
reminders, (b) electronic monitoring and (c) combined reminders and group support from other patients. The
interventions, termed INTV1, INTV2, and INTV3, are shown in Figure 2. INTV1 is based on reminders and can be
supported by a mobile application or specialized software on a mobile device. INTV2 is based on communication with
a smart medication box that keeps track of doses and timing. INTV3 can be supported by a website that allows patients
to interact with one another and also receive educational information related to their specific conditions.
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Figure 1: The Design Approach for Technological Interventions

Figure 2: Three Interventions for Preventing Prescription Opioid Abuse
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The Figure 3 shows the operationalization of the intervention 1. This includes sending a reminder to patient at the
prescribed time if the patient has not taken the dose already. As shown in Figure 3(a), the reminder app (Rem-App)
sends a message to the patient to take the opioid dose within the time-window. The app also tells the patient to wait
for the next dose until the next reminder. Finally, the Rem-App detects the patient’s mood for its context-aware
operation. As shown in Figure 3(b), the CBT-OP helps patient on the potential side effects of the opioids, motivation
for exercise, healthy eating habits, managing stress, and keeping doctor’s appointment. It asks healthcare professionals
(HP) to intervene if doses taken too closely or more frequently or more doses at a time than prescribed (analysis of
consumption patterns).

(a) Rem-App: App for Reminder

(b) CBT-OP: Cognitive Behavior Therapy for Opioids
Figure 3: Operationalization of Intervention 1 (Context-aware Reminders)
The Figure 4 shows the operationalization of the intervention 2. The prescription opioid app (PO-App) retrieves dosing
consumption data from the smart medication box. The consumption history is analyzed by the PO-App and if any
abnormal patterns or behaviors are found then the healthcare professionals are contacted for a suitable intervention.
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PO-App: Prescription Opioids App
Figure 4: Operationalization of Intervention 2 (Monitoring)
The proposed interventions are compared in Table 1, based on their functions, potential strengths, and limitations.
INTV1 will collect opioid consumption information from the patient and send the reminder to avoid overconsumption.
The potential problems include recall bias of the patient, user interface challenges, and any reliability and access
problems. INTV2 will monitor and analyze opioid consumption information from a smart medication box. The
potential problems include the operation of smart medication box and network access. INTV3 requires a sophisticated
website and highly personalized support to the patient and can be fairly complex.
Table 1: Comparison of Proposed Interventions
Intervention

Functions

Operation

Potential Strengths

INTV1
(Mobile
Reminders)

Simple
Reminder

If taken do not take the next
dose, else if not taken please
take it now
Will only come to maintain
the prescribed opioid dose
Monitoring and analyzing
opioid consumption and
necessary intervention

Reduce
overconsumption

Potential
Limitations
Accuracy and
Effectiveness

Personalized

Complexity

Works with Smart
Medication Boxes and
family
members/healthcare
professionals

Monitoring and
analyzing
overhead, trying to
reach and use the
time of family
member and
healthcare
professionals
The complexity of
group support and
composite
intervention

INTV2
(Electronic
Monitoring)

INTV3
(Composite)

Context-aware
Reminder
Electronic
Monitoring

Composite
(group support,
educational
and reminders)

Integrating the operations of
INTV1, INTV2, and
technical/behavioral
interventions

In addition to
potential strengths of
reminders and
monitoring, effective
due to interventions
and support from
patients

In this paper, we do not study the medical effectiveness of these three interventions, but rather focus on the cost of
these interventions and when these interventions may be suitable. In the future, these interventions can be implemented
and tested with real patients for improving the opioid consumption behavior.
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ANALYTICAL MODEL
Analytical models are the representations of mechanisms that govern natural phenomena that are not fully recognized,
controlled or understood (Tedeschi, 2006). They have become indispensable tools for policy and decision-makers and
researchers (Tedeschi, 2006). However, certain techniques must be used to evaluate mathematical models for
objectives, scope and assumptions, appropriateness or validation, and limitations. Essentially, the model should be
appropriate for its intended purpose under the given conditions. The model is appropriate (Tedeschi, 2006) for
studying opioids in chronic illnesses, where multiple opioids are used over an extended period. The interventions and
their cost can be approximated by the model. Therefore, the model is valid and sound and does what it is supposed to
do (Tedeschi, 2006). Further, the three steps of model validation (Hamilton, 1991): verification of the model,
sensitivity analysis, and evaluation of the model, are performed below.
The verification involved step by step checking of the model and debugging where one or more changes in inputs could
lead to unacceptable output (Hamilton, 1991; Tedeschi, 2006). Further, the model was calibrated using values from
other studies (AHRQ, 2014; Aroke et al., 2018; Mallow, Belk, Topmiller, & Strassels, 2018; NYState, 2018; Schuchat,
Houry, & Guy, 2017; Vivolo-Kantor et al., 2018). The model builds upon prior models, and the results obtained from
the model are also supported by other studies. The model was validated by testing for many known cases to verify its
functioning. Further, the causal relationships of Opioid with pharmacy cost, hospitalization cost, emergency room and
outpatient cost, and the intervention cost for multiple chronic conditions were utilized (AHRQ, 2014; Aroke et al.,
2018). All relationships in the model were verified and additional relationships were derived by utilizing known
relationships.
The sensitivity analysis was performed to test the behavior of every equation in the model (Hamilton, 1991). There are
several ways to perform sensitivity analysis for mathematical models (Christopher Frey & Patil, 2002). We focused on
the nominal range sensitivity, which works well for models where there are no significant interactions among input
values and the ranges of plausible values can be defined (using one’s judgment or from the literature). For our model,
we broadly defined the ranges of all input values, obtained from other studies and expanded even further to cover more
extreme cases. The analysis included combining several input values and measuring outputs for these combinations of
inputs. The results of such analysis are presented in the next section. This also helps in answering “what-if” questions
such as “what if patients lived in a city where hospital costs were lower” or “what if an intervention stopped working”.
The evaluation of the model was done to test the adequacy (or robustness) of the model based on the precision and
accuracy of results (Hamilton, 1991; Tedeschi, 2006). The model is precise as it produces values that are close to one
another in multiple iterations. The model accuracy is based on (a) known relationships and (b) calibration of results for
decision making. To measure accuracy further, we tested our model on input data and results from (AHRQ, 2014; Aroke
et al., 2018; Mallow et al., 2018; NYState, 2018; Schuchat et al., 2017; Vivolo-Kantor et al., 2018). We further evaluated
our model by computing the ROI for all three interventions for low, medium, and high range of input parameters. These
values are in close agreement, so our results on opioid abuse and healthcare cost are validated using published data,
while other results on cost of interventions are extrapolated based on known relationships and available data from
multiple studies.
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Table 2: Input Parameters, Key Values and Sources
Input Parameters
The hospitalization rate
The duration of hospital stays
The daily cost of hospital stays
The rate of emergency room
visits
The cost of emergency room
visits
The outpatient visit rate

Average for opioid abuse
.08 per person/year
(0.05 - 1)
4.35 days
(2-10 days)

(NYState, 2018; Schuchat et al., 2017)

$1884 per day
($1000 - $3000)

(Mallow et al., 2018)

0.086 person/year
(0.05 - 1)
2150
($1000 - $5000)
12 times a year
$458
($200 - $700)
$7078
($4000 - $10000)
$692
($120 - $1000)
6%
(0-20%)
94%
(80-100%)

The cost of outpatient visits
The annual cost of brand name
medication/polypharmacy
The annual cost of generic
medication
Probability of brand name
prescription
Probability of generic
prescription

Source

(Mallow et al., 2018)

(Vivolo-Kantor et al., 2018)
(AHRQ, 2014)
Assumption once a month
(Mallow et al., 2018)
(Aroke et al., 2018)
(Aroke et al., 2018)
(Aroke et al., 2018)
(Aroke et al., 2018)

Several assumptions were made to keep the analytical model tractable and reasonably accurate (Tedeschi, 2006). The
assumptions are:
Assumption 1: The patients are adults and living independently.
Assumption 2: The patients can take opioids as prescribed.
Assumption 3: The patients are willing try one or more interventions.
Assumption 4: It is possible to amortize the cost over multiple patients.
These assumptions could be relaxed in future work. To improve the readability of the analytical model, the notations
used are shown in Table 3.
To develop the model, we focused on healthcare savings which can be derived using the cost of healthcare without
intervention and cost of healthcare with intervention as shown in equation 1:
𝐻𝐶

𝐻𝐶

𝐻𝐶

(1)

As shown in equation 2, the cost of intervention per year can be given as the sum of two ratios: the ratio of fix cost to
the number of patients amortized over the number of years intervention will be used and the ratio of variable cost to
the number of patients.
𝐼𝑁𝑇𝑉

(2)

∗

The probability of prescription 𝑃
is derived as a function of finding a doctor to prescribe opioids
and doctor willing to prescribe 𝐷𝑜𝑐𝑡𝑜𝑟
. Further, the probability that intervention is
𝐷𝑜𝑐𝑡𝑜𝑟
effective is a product of willingness of patient, suitability of intervention to a patient, and whether the intervention is
accurate and reliable.
𝑃

𝑃𝑎𝑡𝑖𝑒𝑛𝑡

𝑃𝑎𝑡𝑖𝑒𝑛𝑡

𝐴𝑐𝑐𝑢𝑟𝑎𝑡𝑒
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Table 3: Notations Used in Analytical Model
Notation
𝐴𝑐𝑐𝑢𝑟𝑎𝑡𝑒
CMIN

Meaning
Intervention is accurate
The cost per minute of cellphone calls

CFHOUR-J

The cost of jth hour for a family member (salary and benefits)

𝐶𝑜𝑠𝑡

The fixed cost of intervention

𝐶𝑜𝑠𝑡

Variable cost of intervention per year

CPHOUR-I

The cost of ith hour for healthcare professionals (salary and benefits)

𝐶𝑆 

The cost of switching from Ith to I+1st intervention

𝐷𝑜𝑐𝑡𝑜𝑟

Finding a doctor to prescribe opioids

𝐷𝑜𝑐𝑡𝑜𝑟

Doctor willing to prescribe

FIMAX
𝐻𝐶

Maximum allowed financial incentive for adoption of an intervention
Healthcare Savings

𝐻𝐶

Cost of healthcare without intervention

𝐻𝐶

Cost of healthcare with intervention

𝐼𝑁𝑇𝑉

Cost of intervention per year
K

NMIN-K
𝑁𝑃
𝑁𝑌𝑅𝐼𝑁𝑇𝑉

The duration to study the benefits of reducing opioid abuse
The number of phone minutes used in the kth day
Number of patients
Number of years intervention will be used

𝑃𝑎𝑡𝑖𝑒𝑛𝑡

Willingness of patient

𝑃𝑎𝑡𝑖𝑒𝑛𝑡

Suitability to a patient

𝑃

Probability of addiction

𝑃

Probability that intervention is effective
𝑃

Probability of prescription

QALY

Quality adjusted life years

QoL
𝑅𝑒𝑙𝑖𝑎𝑏𝑙𝑒

Quality of Life
Intervention is reliable

𝑅𝑂𝐼

Return of Investment

TCI

Total Cost of Intervention

TFHOUR

Total time spent by a family member

TPHOUR

Total time spent per year by healthcare professionals

𝑇𝑜𝑡𝑎𝑙

The total value obtained due to intervention in 1 year
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The cost of interventions includes the cost of training, the ongoing time cost of healthcare professionals or family
members involved, and the cost of communications. The patient's time is not included as suggested by (Windsor et
al., 1990). However, minutes used for cell phone calls are included in the total cost of the intervention. Thus, the
general equation for the total cost of the intervention (TCI) can be given as:
𝑇𝐶𝐼

∑

N

CP

CP

𝐶

𝐼𝑁𝑇𝑉

(4)

where, TPHOUR is the total time spent per year by healthcare professionals and CPHOUR-I is the cost of ith hour for
healthcare professionals including salary and benefits. TFHOUR and CFHOUR-J represent the same factors for a family
member. NMIN-K is the number of phone minutes used in the kth day and CMIN is the cost per minute of a phone call.
DiY represents the number of days in a year. CFIX is the fixed cost of intervention, such as the development cost, and
is amortized over intervention duration and the number of patients covered. CVAR is the variable cost and can include
maintenance cost of the intervention (such as website/servers) amortized over the number of patients. Not all
interventions will have every cost component, but the above equation can be used to derive total cost of interventions
for all three interventions. If the selected intervention is not effective, then the total cost of intervention also includes
the switching cost as follows:
𝑇𝐶𝐼

TCI

where, 𝐶𝑆 

𝐶𝑆 

𝑇𝐶𝐼 

(5)

is the cost of switching from Ith to I+1st intervention.

For an intervention to be cost-effective, the savings have to be more than the total cost of interventions (or HCSavings
>= TCI). To quantify savings to different costs of interventions, we define Return on Investment (ROI) as the ratio of
the product of the probability of prescription, probability of addiction, healthcare savings for addicted patient, and
probability that intervention is effective to the cost of intervention:
𝑅𝑂𝐼

𝑃

𝑃
(6)

𝐻𝐶

𝑃

/𝑇𝐶𝐼

Assuming non-negative quality of improvement values, the total QALY (Quality-adjusted Life Years) gained can be
expressed as the sum of two improvements, one due to additional years obtained and another due to quality of life
improvement in the existing years. However, we can focus on 1-year benefit, so the QALY gained is equal to the
Quality of Life improvement when the patient does not have opioid abuse. Thus, the total value obtained in 1 year is
the product of cost equivalent of one QALY and the number of QALY gained due to the intervention:
𝑇𝑜𝑡𝑎𝑙

𝐶

𝑁

(7)

Now, we explore the use of financial incentive for the adoption of an intervention (not given as cash, but to meet
insurance deductible/co-pay/out-of-pocket). The maximum value of this financial incentive over a year can be given
as follows:
𝐹𝐼

𝑃

𝑃

𝐻𝐶

𝑃

𝑇𝐶𝐼

(8)

We are currently modeling a utility function involving personalized interventions for patients and patient’s desirability
for the interventions and outcomes. We will also address the optimization of this utility function along with
mathematical proofs of lemmas and theorems. This will allow our analytical model to be more generalizable. The
QALY gained will be computed using both the utility and predicted life expectancy.

RESULTS
Although multiple interventions are medically suitable in preventing opioid abuse, we want to evaluate the cost of
interventions and study when and where these interventions are cost-effective. Next, the cost components of various
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interventions are shown in Table 4 along with the values used (BLS, 2018; Page, Horvath, Danilenko, & Williams,
2012; Varshney, 2013). The cost of electronic monitoring is a function of the dosing frequency as additional processing
is required from the healthcare professional every time an opioid is consumed or scheduled. Mobile reminders are the
simplest intervention while composite intervention is likely to be most effective. The cost of the mobile application is
varied from zero to ten dollars a month to accommodate different versions (basic, premium, deluxe) of the app.

Table 4: The Cost Components of Various Interventions
The
Intervention
INTV1: Mobile
Reminders

INTV2: Electronic
Monitoring

Included Components

Time (Total Cost)

Training of a nurse
(one-time initial cost)
One phone call per day
Rest two calls as recorded
messages
Mobile App cost per month
Training and installation

2, 3 and 4 hours
($40, $60, $80)
5 minutes ($1.67)
2 minutes
($0.67)
0, $5, $10
2, 3 and 4 hours
($40, $60, $80)
2 minutes
($0.67)
5 minutes ($1.67)
$100, $300, $500

Messages

INTV3: Composite

Message Processing by a Nurse
Cost of Monitoring
System/Software
Informational Material
Reminder
Group Support
Specialized Application

$500,000
developmental cost
$5000/month
maintenance cost
30 minutes ($20/hour
cost=$10)

Family/Healthcare professional

Total Cost of Intervention
(TCI)
(Low, Medium, High)
$1099, $1179, $1259

$1199, $1419, $1639

$1080 (1000 patients),
$1453 (600 patients),
$3320 (200 patients)

The ROI for different interventions is shown in Table 5. We included low, medium and high values of parameters, to
cover many different scenarios, in deriving ROI. The ROI is <1 (shown in red) for low and medium values of our
input parameters, while it is much more favorable when the values of the parameters are set to high. For the same
level of effectiveness, INTV3 is cost-effective only for 100% medical effectiveness and high value of parameters.
Table 5: ROI for Various Types and Level of Intervention Effectiveness
ROI
INTV1
INTV2
INTV3
Low
Medium
High Low
Medium
High Low
Medium
High
25%
0.0005
0.04 0.66 0.0005
0.03 0.51 0.0005
0.03 0.25
50%
0.001
0.08 1.32 0.0015
0.09 1.53
0.001
0.06
0.5
75%
0.0015
0.12 1.98 0.0015
0.09 1.53 0.0015
0.09 0.75
100%
0.002
0.16 2.64
0.002
0.12 2.04
0.002
0.12
1
Low, Medium, and High range for following input parameters:
Hospitalization, Number of days, Cost/day, Emergency visit rate, Emergency cost/visit, Probability of addiction
Effectiveness

Next, we decided to include the value due to a potential improvement in Quality of Life (QoL). The ROI for different
interventions with QoL included is shown in Table 6. Now, the ROI is <1 (shown in red) only for low values of our
parameters, while it is much more favorable (shown in green) when the values of the parameters are set to medium or
high.
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Table 6: ROI for Different Interventions with Quality of Life Improvement

Effectiveness
25%
50%
75%
100%

Low
0.0232
0.0464
0.0697
0.0928

INTV1
Medium
0.57
1.14
1.71
2.28

High
2.646
5.292
7.938
10.584

ROI with QoL
INTV2
Low
Medium High
0.0214
0.47
2.035
0.0427
0.941
4.071
0.0641
1.411
6.106
0.0854
1.882
8.141

Low
0.0236
0.0473
0.0709
0.0946

INTV3
Medium
0.4601
0.9203
1.38
1.841

High
1.003
2.006
3.009
4.012

Low, Medium, and High range for following input parameters:
Hospitalization, Number of days, Cost/day, Emergency visit rate, Emergency cost/visit, Probability of addiction, QoL

Next, we decided to add a financial incentive (not cash, but payment for insurance deductible, out-of-pocket expenses
or co-pay for general healthcare and wellness) to improve the adoption of three interventions by patients. We wanted
to compute the maximum allowed financial incentives that can be offered to the patients while still meeting the costeffectiveness goal for the interventions. Based on the medical effectiveness level of intervention, the range of financial
incentives varies from $165-$1509 for INTV1 for medium values and $2066-$12041 for high values. Similar numbers
are $597-$1269 for INTV2 for medium values and $1686-$11661 for high values. The numbers and range for INTV3
for medium values are $563-$1235 and $5-$9980 for high values.
Table 7: Maximum Allowed Financial Incentives

Effectiveness
25%
50%
75%
100%

Low
0
0
0
0

Maximum Allowed Financial Incentives/Year with QoL
INTV1
INTV2
INTV3
Medium
High
Low Medium
High
Low
Medium
0
$2066
0
0
$1686
0
0
$165
$5391
0
0
$5011
0
0
$837
$8716
0
$597
$8336
0
$563
$1509
$12041
0
$1269
$11661
0
$1235

High
$5
$3330
$6655
$9980

Low, Medium, and High range for following input parameters:
Hospitalization, Number of days, Cost/day, Emergency visit rate, Emergency cost/visit, Probability of addiction, QoL

DISCUSSION, CONCLUSION AND FUTURE WORK
Prescription opioid abuse can lead to addiction, higher healthcare costs, and serious harm to patients. This abuse
requires detoxification and hospitalization similar to a chronic condition. One of the major observations from the
literature is that only 10% of people with opioid abuse get treatment or help. Therefore, the opioid abuse is a major
challenge for patients and family members, healthcare professionals, employers, regulators, and the society. There is
a need for interventions at multiple levels before patients develop opioid addiction and require major treatment. In this
paper, we focused on patient-level interventions, which are proactive and with some probabilities will be effective for
some patients in preventing them from developing an opioid addiction. The interventions are (a) mobile reminders,
(b) electronic monitoring of opioids, and (c) composite intervention.
Using prescription opioid abuse and intervention data, we derived the healthcare cost of opioid abuse along with the
cost of three interventions. Using an analytical model and ROI (Return on Investment) as a metric for costeffectiveness of interventions, we derived several results for all three interventions and various levels of effectiveness.
We found that ROI is lower than 1 for low and medium values of our parameters, while it is much more favorable
when the values of the parameters are set to high. When the value due to a potential improvement in Quality of Life
was included, the ROI significantly improved for all three interventions. Further, we wanted to explore if the use of
financial incentives will be suitable to improve the adoption of three interventions. For this, we computed the
maximum allowed financial incentives that can be offered to the patients while still meeting the cost-effectiveness
goal for the interventions.
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We are planning to conduct a meta-analysis/contextual analysis of data from multiple sources to further evaluate the
model. We are comparing the IT-based interventions with the non-IT interventions for opioid abuse. The scope for
future research includes a randomized controlled trial (RCT) to evaluate the medical effectiveness of three proposed
interventions. The research can be further extended to field studies using Health Promotion Model, Theory of
Addiction, Theory of Adaptation, and other theories on drug abuse.
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